How to Prevent Recurrent Cancer
Recurrent Cancer Overview
The initial cancer treatment given to new patients generally comes from traditional "standard of care" guidelines; by way of example, breast cancer may be a surgical removal of the breast followed by systemic chemotherapy and radiation.
This "1st line therapy" is considered the best approach based upon type and stage of cancer – but if not "cured," or patient experiences severe side effects, then another treatment may be added or used instead.
Regrettably, 1st line therapy often fails to kill all existing cancer cells; often reappearing at the original tumor site months later, a new distant site, or both, with treatment now considered palliative rather than curative, and; sadly, depriving the patient the chance to be free of recurrent cancer forever.
Recurrent Cancer Insights
1st-Line Recurrent Cancer Prevention
1st line therapy recurrence can be prevented if low-dose radiation, et al are given immediately preceding the patient undergoing an initial biopsy or the initial treatment!
How? it's well accepted that low-dose radiation can significantly reduce or even obviate lethal cancer tumor cells in surrounding tumor margins and regional lymphatic areas when combined with a chemo-sensitizing cytostatic agent. This combination of chemotherapy and radiation is called cytoreduction ("CCRT"), or more commonly "neoadjuvancy" However, neoadjuvancy was never expected or intended to eliminate the tumor in its entirety, rather:
The prophylactic use of a low-dose chemo agent immediately preceding and immediately following 1st line surgery, has shown to provide the greatest protection for lethal cancerous cells spreading during an initial biopsy or tumor surgery; it can also help overlap the gap between the 1st line surgery and any subsequent invasive treatment(s).
In all instances this is best achieved when CCRT is administered immediately following full recovery of the patient (usually 4 to 6 weeks after surgery) when a small dose of radiation and low-dose chemotherapy is given within the same cancer "fields" and identically as given previously; with the primary intent to eliminate the potential for lethal "surgical seeding" and/or any remaining localized malignant cells.
This proprietary neoadjuvancy protocol has been the mainstay of our treatment approach for over 40 years of practice and enabled us to achieve remission for tens of hundreds of past patients, with many remaining cancer-free for over 10 to 20 years!